Response to Comments: Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin’s and Non-Hodgkin’s Lymphoma with B-Cell or T-Cell Origin

This article is a response-to-comments regarding the proposed LCD for allogeneic hematopoietic cell transplantation in relapsed or primary refractory Hodgkin and non-Hodgkin lymphoma; it summarizes comment and notice periods and notes the LCD became final on 2023-03-05. The document does not state clinical coverage indications, limitations, or frequency limits—consult the final LCD A59326 for the specific medical necessity criteria and coverage rules.

"This response-to-comments document does not itself define clinical coverage criteria; coverage determinations should be based on the final Local Coverage Determination (LCD) A59326 rather than this..."

Sign up to see full coverage criteria, indications, and limitations.